The MD Anderson Cancer Center is conducting a study on an immunotherapy drug that is specifically for rare, advanced tumors. Pleural and peritoneal mesothelioma are both included in the study. The clinical trial is looking for effectiveness and safety of vudalimab. The treatment, also known as XmAb20717, was created by[…]
Opdivo (nivolumab)
Checkmate 743 Shows Immunotherapy is Better for Mesothelioma Patients Who Cannot Receive Surgery
A clinical trial called Checkmate 743, which looks at the immunotherapy drugs nivolumab (Opdivo) and ipilimumab (Yervoy), shows that the combination can create a better quality of life when compared with the chemotherapy drugs pemetrexed, cisplatin, and carboplatin. Patient reported outcomes were recently reported. People who took Opdivo and Yervoy[…]
LMB-100 and Ipilumab Combination Being Tested for Pleural and Peritoneal Mesothelioma
The National Cancer Institute just started a study to see if it could make immunotherapy more potent for treating mesothelioma. The study combines a manmade protein that kills cancer cells called LMB-100 and an immunotherapy drug called ipilumab. The problem with current immunotherapy treatments is they do not work well[…]
A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
Primary Outcome Measures Major Pathologic (Disease) Response of Tumor to Nivolumab Combined with Ipilimumab Before Surgery [ Time Frame: 24 months ] The response of participant’s tumor to treatment with nivolumab and ipilimumab before surgery by analyzing tissue samples collected from participant during surgery for the presence of cancerous tumour cells. Major pathologic response[…]
GPS Vaccine is Effective in Mesothelioma Patients When Paired with Opdivo
A new cancer vaccine was found to be effective in mesothelioma patients alongside Opdivo in a new study. It was studied in people whose cancer no longer responded to standard chemotherapy. The phase I clinical trial took place at the Memorial Sloan Kettering Cancer Center and it involved the galinpepimut-S[…]
Mesothelioma Patients with High Levels of the PD-L1 Protein Have Shorter Survival
Unfortunately for mesothelioma patients with high levels of the PD-L1 protein, they have a worse overall survival compared to patients who have lower levels. A European study looking at 200 patients wanted to see if PD-L1 and PD-1, popular targets for immunotherapy drugs, impact survival independently without immunotherapy drugs present.[…]
A Phase III Clinical Trial is Looking at the Combination of Durvalumab and Chemotherapy to Treat Mesothelioma
A new clinical trial involving durvalumab should be closely monitored by the Food and Drug Administration. The phase III clinical trial is being performed in Baltimore, Cleveland, and Ann Arbor as well as places in New Zealand and Australia. The randomized trial is known as DREAM3R. It wants to figure[…]
Researchers are Developing a Test to Determine Which Mesothelioma Patients Will Benefit From Immunotherapy
Doctors want to figure out which pleural mesothelioma patients will best benefit from certain chemotherapy drugs. Currently there are no tests to see what immunotherapy drugs might work on a specific patient. This leads to doctors trying out different treatments that have negative side effects to only find out the[…]
The ONCOS-102 Vaccine Was Just Given the Fast-Track Designation
The ONCOS-102 immunotherapy vaccine was given the Fast-Track Designation, which will speed up regulatory approval. The vaccine is used to treat mesothelioma and other cancers. Targovax, which developed the treatment, is taking this as an endorsement from the FDA. Targovax is a small biotech company that mainly works with oncolytic[…]
Nivolumab Can Help Increase the Survival in Mesothelioma Patients Whose Cancer Has Relapsed
A study in the United Kingdom involving 332 patients who cannot receive surgery (unresectable) found that patients whose mesothelioma has relapsed can be treated with nivolumab safely. Nivolumab is an immunotherapy drug known as Opdivo, which is popular for treating non-small cell lung cancer. Opdivo is promising because it is[…]
Skip to content